Cost-efficacy of capecitabine and docetaxel in combination compared with docetaxel monotherapy in patients with metastatic breast cancer pre-treated with antracyclines;Costo-efficacia di capecitabina in combinazione con docetaxel versus docetaxel in monoterapia nel trattamento del carcinoma alla mammella metastatico in pazienti pretrattate con antracicline

PharmacoEconomics - Italian Research Articles

Volumn 7, Issue 1, 2005, Pages 59-66

  Ravasio, Roberto ^a   Giuliani, G ^b   Veronesi, A ^c  

^a Adis International Ltd   (Italy)

^b ROCHE MILANO RICERCHE   (Italy)

^c CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE DERIVATIVE; CAPECITABINE; DOCETAXEL;

ADULT; ARTICLE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DATA ANALYSIS; FEMALE; HEALTH ECONOMICS; HUMAN; MAJOR CLINICAL STUDY; MEDICAL LITERATURE; METASTASIS; MONOTHERAPY; ONCOLOGICAL PARAMETERS; QUALITY ADJUSTED LIFE YEAR; RANDOMIZED CONTROLLED TRIAL; SENSITIVITY ANALYSIS; TREATMENT OUTCOME;

EID: 14844337496     PISSN: 15909158     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03320535     Document Type: Article

References (20)

1. http://www.unisi.it/creditimed/vari_pdf/neri_chirurgia.pdf
2. Crocetti E, Capocaccia R, Casella C, et al. Gli andamenti temporali della patologia in Italia: i dati registri dei tumori (1986-97). Epidemiol Prev 2004; 28 (Suppl. 2): 1-6
3. Zanetti R, Roso S, Spitale A, et al. Fatti e cifre dei tumori in Italia. Roma: Il Pensiero Scientifico Editore, 2003
4. http://www.ica33.it/argomenti/sanita/sanita.asp
5. http://www.portalemedico.it/ modules.php?name=News&file=article&sid=104
6. Bonadonna G, Robustelli della Cuna G. Manuale di oncologia medica. Milano: Masson, 1999
7. O'Shaughnessy J, Miles D, Vukelja S, et al. Superior with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: Phase III trial results. J Clin Oncol 2002; 20 (12): 2812-23
8. Launois R, Reboul-Marty J, Henry B, Bonneterre J. A cost-utility analysis of second-line chemotherpy in metastatic breast cancer. Docetaxel versus paclitaxel versus vinorelbine. Pharmacoeconomics 1996; 10 (5): 504-21
9. Hutton J, Brown R, Borowitz M, et al. A new decision model for cost-utility comparison of chemotherapy in recurrent metastatic breast cancer. Pharmacoeconomics 1996; 9 (Suppl. 2): 8-22
10. Brown R, Hutton J. Cost-utility model docetaxel and paclitaxel in advanced breast cancer patients. Anticancer Drugs 1998; 9 (10): 899-907
11. Bondonio P, Eandi M. Tempi e costi di lavoro associati al trattamento farmacologico: analisi di alcune opportunità di risparmio. Farmeconomia 1995; 2 (3): 36-45
12. Lucioni C, Mazzi S, Neeser K, et al. Analisi di cost-efficacia della terapia combinata con pioglitazone nel trattamento del diabete mellito di tipo 2 in Italia. Pharmacoeconomics - Italian Research Articles 2004; 6 (2): 81-93
13. Lucioni C, Garancini MP, Massi-Benedetti M, et al. Il costo sociale del diabete di tipo 2 in Italia: lo studio CODE-2. Pharmacoeconomics - Italian Research Articles 2000; 2 (1): 1-21
14. Verma S, Ilersich AL. Population-based phamacoeconomic model for adopting capecitabine/docetaxel combination treatment for anthracycline-pretreated metastatic breast cancer. Oncologist 2002; 8 (3): 232-40
15. O'Shaughnessy JA. Capecitabine and docetaxel in advanced breast cancer: analysis of phase III comparative trial. Oncology (Huntington) 2002; 16 (10 Suppl. 12): 17-22
16. Wright TL, Twelves CJ. Improved survival in advanced breast cancer with docetaxel and capecitabine in combination: biological synergy or an artefact of trial design? Eur J Cancer 2002; 38 (15): 1957-60
17. Tengs TO, Adams ME, Pliskin JS, et al. Five-hundred life-saving interventions and their cost-effectiveness. Risk Anal 1995; 15 (3): 369-90
18. George B, Harris A, Mitchell A. Cost-effectiveness analysis and the consistency of decision making: evidence from pharmaceutical reimbursement in Australia (1991 to 1996). Pharmacoeconomics 2001; 19 (11): 1103-9
19. http://www.nice.org.uk/
20. Messori A, Santarlasci B, Trippoli S. Guadagno di sopravvivenza dei nuovi farmaci. Pharmacoeconomics-Italian Research Articles 2004; 6 (2): 95-104